BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients
Authors
Keywords
Colorectal cancer, <em class=EmphasisTypeItalic >BRAF</em>, <em class=EmphasisTypeItalic >KRAS</em>, Survival, Prognosis
Journal
BMC CANCER
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-11-03
DOI
10.1186/1471-2407-14-802
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer
- (2017) Jianfei Wang et al. Cancer Biomarkers
- Clinical relevance of KRAS mutations in codon 13: Where are we?
- (2013) Tze-Kiong Er et al. CANCER LETTERS
- Colon and Rectal Cancer Survival by Tumor Location and Microsatellite Instability
- (2013) Amanda I. Phipps et al. DISEASES OF THE COLON & RECTUM
- Detection of KRAS Mutations and Their Associations with Clinicopathological Features and Survival in Chinese Colorectal Cancer Patients
- (2013) Z Li et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
- (2013) Chih-Chieh Chen et al. PLoS One
- Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling of KRAS, BRAF, PIK3CA, NRAS Mutations in Colorectal Cancer Characteristics and Personalized Medicine
- (2013) Yinchen Shen et al. PLoS One
- Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population
- (2012) Li-Ling Hsieh et al. CLINICA CHIMICA ACTA
- Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers
- (2012) Y. Imamura et al. CLINICAL CANCER RESEARCH
- How many molecular subtypes? Implications of the unique tumor principle in personalized medicine
- (2012) Shuji Ogino et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer
- (2012) Chen Mao et al. PLoS One
- PI3K expression and PIK3CA mutations are related to colorectal cancer metastases
- (2012) Yu-Fen Zhu WORLD JOURNAL OF GASTROENTEROLOGY
- BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
- (2011) T Yokota et al. BRITISH JOURNAL OF CANCER
- Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients
- (2011) Jing Gao et al. Chinese Journal of Cancer Research
- Gene Expression Differences between Colon and Rectum Tumors
- (2011) R. Sanz-Pamplona et al. CLINICAL CANCER RESEARCH
- Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
- (2011) Cecily P. Vaughn et al. GENES CHROMOSOMES & CANCER
- Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population
- (2011) Jyh-Ming Liou et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients
- (2011) Hong Shen WORLD JOURNAL OF GASTROENTEROLOGY
- The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
- (2010) A. Fariña-Sarasqueta et al. ANNALS OF ONCOLOGY
- Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer
- (2010) Inti Zlobec et al. INTERNATIONAL JOURNAL OF CANCER
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients
- (2009) Y. He et al. CLINICAL CANCER RESEARCH
- KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803
- (2009) S. Ogino et al. CLINICAL CANCER RESEARCH
- KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
- (2009) Susan D. Richman et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- (2009) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CAMutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
- (2009) Shuji Ogino et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
- (2009) Andrea Sartore-Bianchi et al. PLoS One
- Asia Pacific consensus recommendations for colorectal cancer screening
- (2008) J J Y Sung et al. GUT
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started